Compound 641
Identifiers
- Canonical SMILES:
CCc1ccc2O[C@@H](C3=C(N(C)c4ncnn4[C@H]3c3ccc(Br)cc3)c2c1)c1ccc(Br)cc1
- InChi:
InChI=1S/C27H22Br2N4O/c1-3-16-4-13-22-21(14-16)25-23(26(34-22)18-7-11-20(29)12-8-18)24(17-5-9-19(28)10-6-17)33-27(32(25)2)30-15-31-33/h4-15,24,26H,3H2,1-2H3/t24-,26+/m0/s1
- InChiKey:
VBADVYAYXYBYJN-AZGAKELHSA-N
External links
44549892 |
External search
Bibliography (1)
Pharmacological data
Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|
1 | 0 | 0 | 0 |
Targets
PPI family | Best activity | Diseases | MMoA |
---|---|---|---|
MDM2-Like / P53 | 5.49 | cancer | Inhibition |
Physicochemical filters
Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
---|---|---|---|---|
Compliance | ||||
MW | 576.02 g/mol | |||
HBA | 5 | |||
HBD | 0 | |||
HBA + HBD | 5 | |||
AlogP | 7.46 | |||
TPSA | 43.18 | |||
RB | 3 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|---|
1 | 1 | 0 | 0 | 0 |
Ta | Structure | Name | Drugbank ID |
---|---|---|---|
0.4255 | BMS-394136 | DB12067 | |
0.3741 | GDC-0927 | DB14934 | |
0.3454 | LY-2881835 | DB15046 | |
0.3424 | (4aS,6R,8aS)-11-[8-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)octyl]-6-hydroxy-3-methoxy-5,6,9,10-tetrahydro-4aH-[1]benzofuro[3a,3,2-ef][2]benzazepin-11-ium | DB02673 | |
0.3397 | Desvancosaminyl vancomycin | DB04529 | |
0.3395 | Parsaclisib | DB14867 | |
0.3377 | Naldemedine | DB11691 | |
0.3369 | Vancomycin | DB00512 | |
0.3353 | MK-1775 | DB11740 | |
0.3333 | Rocaglamide | DB15495 | |
0.3325 | Balhimycin | DB04111 | |
0.3322 | Galicaftor | DB14894 | |
0.3322 | Iclaprim | DB06358 | |
0.3322 | (S)-iclaprim | DB07938 | |
0.3322 | 5-[[(2R)-2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl]methyl]pyrimidine-2,4-diamine | DB08741 |